IMED PHARMA LIMITED

Company Registration Number:
08380253 (England and Wales)

Unaudited abridged accounts for the year ended 31 December 2023

Period of accounts

Start date: 01 January 2023

End date: 31 December 2023

IMED PHARMA LIMITED

Contents of the Financial Statements

for the Period Ended 31 December 2023

Balance sheet
Notes

IMED PHARMA LIMITED

Balance sheet

As at 31 December 2023


Notes

2023

8 months to 31 December 2022


£

£
Fixed assets
Intangible assets: 3 1,199,427 1,276,324
Tangible assets: 4 344,731 360,376
Total fixed assets: 1,544,158 1,636,700
Current assets
Stocks: 125,877 146,654
Debtors: 5 268,681 289,477
Cash at bank and in hand: 208,643 374,587
Total current assets: 603,201 810,718
Creditors: amounts falling due within one year: 6 (1,305,163) (2,131,283)
Net current assets (liabilities): (701,962) (1,320,565)
Total assets less current liabilities: 842,196 316,135
Creditors: amounts falling due after more than one year: 7 (562,898)
Provision for liabilities: (8,018) (10,027)
Total net assets (liabilities): 271,280 306,108
Capital and reserves
Called up share capital: 100 100
Profit and loss account: 271,180 306,008
Shareholders funds: 271,280 306,108

The notes form part of these financial statements

IMED PHARMA LIMITED

Balance sheet statements

For the year ending 31 December 2023 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

The members have agreed to the preparation of abridged accounts for this accounting period in accordance with Section 444(2A).

These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The directors have chosen to not file a copy of the company’s profit & loss account.

This report was approved by the board of directors on 23 September 2024
and signed on behalf of the board by:

Name: A Tanna
Status: Director

The notes form part of these financial statements

IMED PHARMA LIMITED

Notes to the Financial Statements

for the Period Ended 31 December 2023

1. Accounting policies

These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

IMED PHARMA LIMITED

Notes to the Financial Statements

for the Period Ended 31 December 2023

2. Employees

2023 8 months to 31 December 2022
Average number of employees during the period 12 11

IMED PHARMA LIMITED

Notes to the Financial Statements

for the Period Ended 31 December 2023

3. Intangible Assets

Total
Cost £
At 01 January 2023 1,624,743
At 31 December 2023 1,624,743
Amortisation
At 01 January 2023 348,419
Charge for year 76,897
At 31 December 2023 425,316
Net book value
At 31 December 2023 1,199,427
At 31 December 2022 1,276,324

IMED PHARMA LIMITED

Notes to the Financial Statements

for the Period Ended 31 December 2023

4. Tangible Assets

Total
Cost £
At 01 January 2023 439,083
Additions 2,296
At 31 December 2023 441,379
Depreciation
At 01 January 2023 78,707
Charge for year 17,941
At 31 December 2023 96,648
Net book value
At 31 December 2023 344,731
At 31 December 2022 360,376

IMED PHARMA LIMITED

Notes to the Financial Statements

for the Period Ended 31 December 2023

5. Debtors

2023 2022 Trade debtors 186,319 206,561 Other debtors 43,910 51,753 Prepayments 38,452 31,163 Total Debtors 268,681 289,477

IMED PHARMA LIMITED

Notes to the Financial Statements

for the Period Ended 31 December 2023

6. Creditors: amounts falling due within one year note

2023 2022 Bank borrowings 23,506 - Other borrowings 3,740 1,961 Trade creditors 240,820 324,616 Amounts due to related parties 1,000,000 1,696,690 Social security and other taxes 2,182 - Outstanding defined contribution pension costs 338 834 Other creditors 34,577 107,182 Total creditors due within one year 1,305,163 2,131,283

IMED PHARMA LIMITED

Notes to the Financial Statements

for the Period Ended 31 December 2023

7. Creditors: amounts falling due after more than one year note

2023 2022 Bank borrowings 562,898 -

IMED PHARMA LIMITED

Notes to the Financial Statements

for the Period Ended 31 December 2023

8. Related party transactions

Name of the related party:
Relationship:
Directors
Description of the Transaction: 2023 2022 Amounts owing by company to directors 3,740 1,961
£
Balance at 01 January 2023 1,961
Balance at 31 December 2023 3,740
Name of the related party:
Relationship:
Parent
Description of the Transaction: 2023 2022 Owing to Parent 1,000,000 1,696,690
£
Balance at 01 January 2023 1,696,690
Balance at 31 December 2023 1,000,000

Key management personnel are considered to be the directors of the company